JP2015512951A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512951A5 JP2015512951A5 JP2015505972A JP2015505972A JP2015512951A5 JP 2015512951 A5 JP2015512951 A5 JP 2015512951A5 JP 2015505972 A JP2015505972 A JP 2015505972A JP 2015505972 A JP2015505972 A JP 2015505972A JP 2015512951 A5 JP2015512951 A5 JP 2015512951A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- disorder
- dementia
- pharmaceutical composition
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical group 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 238000013019 agitation Methods 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000015046 intermittent explosive disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000000697 serotonin reuptake Effects 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624291P | 2012-04-14 | 2012-04-14 | |
| US201261624293P | 2012-04-14 | 2012-04-14 | |
| US201261624292P | 2012-04-14 | 2012-04-14 | |
| US61/624,293 | 2012-04-14 | ||
| US61/624,292 | 2012-04-14 | ||
| US61/624,291 | 2012-04-14 | ||
| US201261671723P | 2012-07-14 | 2012-07-14 | |
| US201261671713P | 2012-07-14 | 2012-07-14 | |
| US61/671,713 | 2012-07-14 | ||
| US61/671,723 | 2012-07-14 | ||
| PCT/US2013/036514 WO2013155505A1 (en) | 2012-04-14 | 2013-04-14 | Organic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512951A JP2015512951A (ja) | 2015-04-30 |
| JP2015512951A5 true JP2015512951A5 (enExample) | 2016-06-09 |
| JP6242855B2 JP6242855B2 (ja) | 2017-12-06 |
Family
ID=49328233
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505972A Active JP6242855B2 (ja) | 2012-04-14 | 2013-04-14 | 有機化合物 |
| JP2015505973A Withdrawn JP2015514135A (ja) | 2012-04-14 | 2013-04-14 | 新規組成物および方法 |
| JP2015505971A Active JP6334511B2 (ja) | 2012-04-14 | 2013-04-14 | 新規方法 |
| JP2018107717A Withdrawn JP2018168161A (ja) | 2012-04-14 | 2018-06-05 | 新規組成物および方法 |
| JP2021035948A Pending JP2021098724A (ja) | 2012-04-14 | 2021-03-08 | 新規組成物および方法 |
| JP2023136052A Pending JP2023159345A (ja) | 2012-04-14 | 2023-08-24 | 新規組成物および方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505973A Withdrawn JP2015514135A (ja) | 2012-04-14 | 2013-04-14 | 新規組成物および方法 |
| JP2015505971A Active JP6334511B2 (ja) | 2012-04-14 | 2013-04-14 | 新規方法 |
| JP2018107717A Withdrawn JP2018168161A (ja) | 2012-04-14 | 2018-06-05 | 新規組成物および方法 |
| JP2021035948A Pending JP2021098724A (ja) | 2012-04-14 | 2021-03-08 | 新規組成物および方法 |
| JP2023136052A Pending JP2023159345A (ja) | 2012-04-14 | 2023-08-24 | 新規組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US20150080404A1 (enExample) |
| EP (4) | EP2836211B1 (enExample) |
| JP (6) | JP6242855B2 (enExample) |
| KR (1) | KR20140146192A (enExample) |
| CN (1) | CN104519886B (enExample) |
| AU (1) | AU2013245702A1 (enExample) |
| CA (1) | CA2870303A1 (enExample) |
| ES (1) | ES2727815T3 (enExample) |
| IN (1) | IN2014DN08562A (enExample) |
| MX (1) | MX2014012374A (enExample) |
| RU (1) | RU2014145682A (enExample) |
| WO (3) | WO2013155504A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2776889T3 (es) | 2007-03-12 | 2020-08-03 | Intra Cellular Therapies Inc | Síntesis de gamma-carbolinas condensadas a heterociclo sustituido |
| CN102046175B (zh) | 2008-03-12 | 2015-08-12 | 细胞内治疗公司 | 取代的杂环稠合的γ-咔啉固体 |
| CN102105059B (zh) | 2008-05-27 | 2015-09-30 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
| JP5894574B2 (ja) | 2010-04-22 | 2016-03-30 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| US10039813B2 (en) | 2012-02-07 | 2018-08-07 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| CN104519886B (zh) | 2012-04-14 | 2017-09-12 | 细胞内治疗公司 | 有机化合物 |
| DK2968320T3 (da) | 2013-03-15 | 2021-02-01 | Intra Cellular Therapies Inc | Organiske forbindelser |
| US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| CN114366741A (zh) | 2013-12-03 | 2022-04-19 | 细胞内治疗公司 | 新方法 |
| KR20170012210A (ko) * | 2014-04-04 | 2017-02-02 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| CA2944755A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN104003987B (zh) * | 2014-06-03 | 2016-03-23 | 中国药科大学 | 他克林-β-咔啉异二连体类多功能胆碱酯酶抑制剂 |
| US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| WO2016138099A1 (en) | 2015-02-24 | 2016-09-01 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| US20170007618A1 (en) * | 2015-06-17 | 2017-01-12 | Massachusetts Institute Of Technology | Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders |
| KR102735964B1 (ko) * | 2016-01-26 | 2024-11-28 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| HUE055334T2 (hu) | 2016-03-25 | 2021-11-29 | Intra Cellular Therapies Inc | Szerves vegyületek és azok alkalmazása központi idegrendszeri betegségek kezelésében vagy megelõzésében |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| US10654854B2 (en) | 2016-03-28 | 2020-05-19 | Intra-Cellular Therapies, Inc. | Salts and crystals of ITI-007 |
| JP6997718B2 (ja) | 2016-03-28 | 2022-01-18 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規共結晶 |
| WO2018071233A1 (en) | 2016-10-12 | 2018-04-19 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3562484B1 (en) | 2016-12-29 | 2021-08-25 | Intra-Cellular Therapies, Inc. | Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders |
| CA3053540A1 (en) * | 2017-02-15 | 2018-08-23 | The Regents Of The University Of California | Improved light therapy system and methods of use |
| US11433253B2 (en) | 2017-02-15 | 2022-09-06 | The Regents Of The University Of California | Light therapy system and methods of use |
| BR112019019875A2 (pt) * | 2017-03-24 | 2020-04-22 | Intra Cellular Therapies Inc | novas composições e métodos |
| WO2018189646A1 (en) | 2017-04-10 | 2018-10-18 | Dr. Reddy's Laboratories Limited | AMORPHOUS FORM AND SOLID DISPERSIONS OF LUMATEPERONE p-TOSYLATE |
| IL272249B2 (en) * | 2017-07-26 | 2023-11-01 | Intra Cellular Therapies Inc | organic compounds |
| IL272252B2 (en) | 2017-07-26 | 2024-03-01 | Intra Cellular Therapies Inc | Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment |
| MX2020007271A (es) | 2017-09-26 | 2020-08-17 | Intra Cellular Therapies Inc | Sales y cristales novedosos. |
| WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP2021519271A (ja) | 2018-03-23 | 2021-08-10 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| US12364694B2 (en) | 2018-03-23 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Organic compounds |
| BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
| MX2020013116A (es) | 2018-06-06 | 2021-05-12 | Intra Cellular Therapies Inc | Sales y cristales novedosos. |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| CA3106447A1 (en) * | 2018-06-11 | 2019-12-19 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| CN112585690B (zh) | 2018-06-21 | 2025-04-15 | 阿奎斯蒂弗医疗股份有限公司 | 用于制作含有药物活性物质的个性化个体单位剂量的系统和方法 |
| US12144808B2 (en) | 2018-08-29 | 2024-11-19 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| KR20210052472A (ko) * | 2018-08-31 | 2021-05-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| EP3843738A4 (en) * | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
| CN120789028A (zh) | 2018-09-07 | 2025-10-17 | 阿奎蒂夫疗法公司 | 具有精确的活性物溶出谱的口腔膜组合物和剂型 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| MX2021007141A (es) | 2018-12-17 | 2021-08-11 | Intra Cellular Therapies Inc | Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido. |
| WO2020131911A1 (en) | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| US12195462B2 (en) | 2018-12-17 | 2025-01-14 | Intra-Cellular Therapies, Inc. | Organic compound |
| EP3897643B1 (en) | 2018-12-21 | 2023-11-15 | Intra-Cellular Therapies, Inc. | A pyridopyrroloquinoxaline compound and its medical use |
| JP7649743B2 (ja) * | 2018-12-21 | 2025-03-21 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| MX2022000143A (es) | 2019-07-07 | 2022-02-17 | Intra Cellular Therapies Inc | Metodos novedosos. |
| US12478623B2 (en) | 2019-09-25 | 2025-11-25 | Intra-Cellular Therapies, Inc. | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor |
| BR112022008294A2 (pt) | 2019-11-01 | 2022-07-26 | Aquestive Therapeutics Inc | Composições de profármaco e métodos de tratamento |
| BR112022008784A2 (pt) | 2019-11-14 | 2022-07-26 | Aquestive Therapeutics Inc | Composições multimodais e métodos de tratamento |
| JP7261942B2 (ja) | 2019-12-11 | 2023-04-20 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| KR20230134136A (ko) | 2021-01-15 | 2023-09-20 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 전구약물 조성물 및 치료 방법 |
| WO2022192476A1 (en) | 2021-03-09 | 2022-09-15 | Aquestive Therapeutics, Inc. | Dosage forms having equivalent biocomparable profiles |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| KR20250012110A (ko) | 2022-05-18 | 2025-01-23 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규 방법 |
| EP4665344A1 (en) * | 2023-02-17 | 2025-12-24 | Intra-Cellular Therapies, Inc. | Lumateperone and derivatives thereof for modulating the nervous system |
| WO2025111568A1 (en) | 2023-11-22 | 2025-05-30 | Intra-Cellular Therapies, Inc. | Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof |
| WO2025240804A1 (en) | 2024-05-16 | 2025-11-20 | Intra-Cellular Therapies, Inc. | Novel compositions, devices and methods |
| WO2025257090A1 (en) | 2024-06-10 | 2025-12-18 | Interquim, S.A. | Process for the preparation of synthesis intermediates of lumateperone and lumateperone analogues |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2490813A (en) | 1944-11-29 | 1949-12-13 | Standard Oil Co | Continuous process for making aryl amines |
| US3299078A (en) | 1962-10-01 | 1967-01-17 | Smith Kline French Lab | Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines |
| US3813392A (en) | 1969-06-09 | 1974-05-28 | J Sellstedt | Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds |
| US3606908A (en) | 1969-11-26 | 1971-09-21 | Trico Products Corp | Ventilation system for volatile fluid |
| US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| JPS5014494A (enExample) * | 1973-06-11 | 1975-02-15 | ||
| IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
| US4001263A (en) | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
| US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4522944A (en) | 1982-12-23 | 1985-06-11 | Erba Farmitalia | Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use |
| SE8304361D0 (sv) * | 1983-08-10 | 1983-08-10 | Ferrosan Ab | Novel 1-acylpiperazine derivatives novel 1-acylpiperazine derivatives |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| JPS6175A (ja) * | 1984-03-06 | 1986-01-06 | ブリストル−マイア−ズ コムパニ− | 神経弛緩剤、１‐フルオロフェニルブチル‐４‐（５‐ハロ‐２‐ピリミジニル）ピペラジン誘導体 |
| IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
| ZA871987B (en) | 1986-03-19 | 1988-05-25 | Kumiai Chemical Industry Co | 5h-1,3,4-thiadiazole(3,2-a)pyrimidin-5-one derivatives and fungicidal compositions containing the same |
| DE3786365T2 (de) | 1986-04-07 | 1993-10-21 | Ihara Chemical Ind Co | 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-on-Derivate und diese enthaltende Gartenbau- und landwirtschaftliche Fungizidmittel. |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| ATE94384T1 (de) | 1989-04-14 | 1993-10-15 | Merz & Co Gmbh & Co | Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie. |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
| CZ293764B6 (cs) | 1993-11-19 | 2004-07-14 | Janssen Pharmaceutica N. V. | Farmaceutický prostředek s dostatečným a dlouhodobým uvolňováním léčiva, biodegradovatelné a biokompatibilní mikročástice, způsob jejich výroby a použití |
| US5576460A (en) | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
| US5654482A (en) | 1996-02-29 | 1997-08-05 | Xerox Corporation | Triarylamine processes |
| US5648539A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Low temperature arylamine processes |
| US5648542A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Arylamine processes |
| US5847166A (en) | 1996-10-10 | 1998-12-08 | Massachusetts Institute Of Technology | Synthesis of aryl ethers |
| US5723669A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| US5705697A (en) | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
| US5723671A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| US6323366B1 (en) | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
| GB2328686B (en) | 1997-08-25 | 2001-09-26 | Sankio Chemical Co Ltd | Method for producing arylamine |
| WO1999018057A1 (en) | 1997-10-06 | 1999-04-15 | Massachusetts Institute Of Technology | Preparation of diaryl ether by condensation reactions |
| US6235936B1 (en) | 1998-02-26 | 2001-05-22 | Massachusetts Institute Of Technology | Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates |
| JP4647780B2 (ja) | 1998-02-26 | 2011-03-09 | マサチューセッツ インスティテュート オブ テクノロジー | ヒドラジン、ヒドラゾン、ヒドロキシルアミンおよびオキシムの金属−触媒アリール化およびビニル化 |
| US5902901A (en) | 1998-05-07 | 1999-05-11 | Xerox Corporation | Arylamine processes |
| US7223879B2 (en) | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| DE69929609T2 (de) | 1998-07-10 | 2006-09-28 | Massachusetts Institute Of Technology, Cambridge | Liganden für metalle und metall-katalysiertes verfahren |
| US6307087B1 (en) | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US20010008942A1 (en) | 1998-12-08 | 2001-07-19 | Buchwald Stephen L. | Synthesis of aryl ethers |
| ATE260642T1 (de) | 1998-12-17 | 2004-03-15 | Alza Corp | Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen |
| US6407092B1 (en) | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
| PE20010052A1 (es) | 1999-04-23 | 2001-01-27 | Upjohn Co | Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht |
| CN1370176A (zh) | 1999-06-15 | 2002-09-18 | 布里斯托尔-迈尔斯斯奎布药品公司 | 取代的杂环稠合γ－咔啉 |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| US6541639B2 (en) | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
| BR0116429A (pt) | 2000-12-20 | 2006-05-09 | Bristol Myers Squibb Co | piridoindóis substituìdos como agonistas e antagonistas da serotonina |
| US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| EP1390340B1 (en) | 2001-04-24 | 2017-03-01 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
| DE60206636T2 (de) | 2001-08-08 | 2006-06-22 | Pharmacia & Upjohn Co. Llc, Kalamazoo | THERAPEUTISCHE 1H-PYRIDO[4,3-b]INDOLE |
| ATE373472T1 (de) | 2002-07-29 | 2007-10-15 | Alza Corp | Verfahren und dosierformen für die kontrollierte abgabe von paliperidon |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| KR20050032107A (ko) | 2002-08-02 | 2005-04-06 | 메사추세츠 인스티튜트 오브 테크놀로지 | 구리를 촉매로 한 탄소-헤테로원자 결합 및 탄소-탄소결합 형성방법 |
| US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
| AU2003287433A1 (en) | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
| PL377426A1 (pl) | 2002-12-19 | 2006-02-06 | Bristol-Myers Squibb Company | Podstawione tricykliczne gamma-karboliny jako agoniści i antagoniści receptora serotoninowego |
| ATE407117T1 (de) | 2003-01-16 | 2008-09-15 | Acadia Pharm Inc | Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen |
| ATE411980T1 (de) | 2003-07-21 | 2008-11-15 | Smithkline Beecham Corp | (2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl) l-phenylalanylü-2-pyrrolidincarbonitril-p- toluolsulfonsäuresalz und wasserfreie kristalline formen davon |
| JP2005259113A (ja) | 2004-02-12 | 2005-09-22 | Ricoh Co Ltd | プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法 |
| WO2005095396A1 (en) | 2004-03-05 | 2005-10-13 | Pharma C S.A. | 8-phenoxy-ϝ carboline derivatives |
| US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
| ES2367868T3 (es) * | 2004-09-20 | 2011-11-10 | Mount Sinai School Of Medicine | Uso de memantina (namenda) para tratar el autismo, la compulsividad y la impulsividad. |
| EP1794114A1 (en) | 2004-09-21 | 2007-06-13 | Pfizer Products Incorporated | N-methyl hydroxyethylamine useful in treating cns conditions |
| ATE457989T1 (de) | 2004-12-15 | 2010-03-15 | Hoffmann La Roche | Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit |
| AU2006255028B2 (en) * | 2005-06-06 | 2012-04-19 | Intra-Cellular Therapies, Inc. | Organic compounds |
| ES2776889T3 (es) | 2007-03-12 | 2020-08-03 | Intra Cellular Therapies Inc | Síntesis de gamma-carbolinas condensadas a heterociclo sustituido |
| CN101842010A (zh) | 2007-08-01 | 2010-09-22 | 梅迪维新神经学公司 | 使用抗精神病的组合治疗产品来治疗精神分裂症的方法和组合物 |
| US8791138B2 (en) | 2008-02-05 | 2014-07-29 | Clera Inc. | Compositions and methods for alleviating depression or improving cognition |
| CN102046175B (zh) | 2008-03-12 | 2015-08-12 | 细胞内治疗公司 | 取代的杂环稠合的γ-咔啉固体 |
| CN102105059B (zh) | 2008-05-27 | 2015-09-30 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
| JP5894574B2 (ja) | 2010-04-22 | 2016-03-30 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| CN104519886B (zh) | 2012-04-14 | 2017-09-12 | 细胞内治疗公司 | 有机化合物 |
| US10011602B2 (en) | 2012-07-06 | 2018-07-03 | The University Of Melbourne | Immunological reagents and uses therefor |
| DK2968320T3 (da) | 2013-03-15 | 2021-02-01 | Intra Cellular Therapies Inc | Organiske forbindelser |
| US9161061B2 (en) | 2013-03-15 | 2015-10-13 | Pictech Management Limited | Data storage and exchange device for color space encoded images |
| CN114366741A (zh) | 2013-12-03 | 2022-04-19 | 细胞内治疗公司 | 新方法 |
| CA2944755A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR20170012210A (ko) | 2014-04-04 | 2017-02-02 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| KR102735964B1 (ko) | 2016-01-26 | 2024-11-28 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| HUE055334T2 (hu) | 2016-03-25 | 2021-11-29 | Intra Cellular Therapies Inc | Szerves vegyületek és azok alkalmazása központi idegrendszeri betegségek kezelésében vagy megelõzésében |
| US10654854B2 (en) | 2016-03-28 | 2020-05-19 | Intra-Cellular Therapies, Inc. | Salts and crystals of ITI-007 |
| WO2018071233A1 (en) | 2016-10-12 | 2018-04-19 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| BR112019019875A2 (pt) | 2017-03-24 | 2020-04-22 | Intra Cellular Therapies Inc | novas composições e métodos |
| IL272249B2 (en) | 2017-07-26 | 2023-11-01 | Intra Cellular Therapies Inc | organic compounds |
| IL272252B2 (en) | 2017-07-26 | 2024-03-01 | Intra Cellular Therapies Inc | Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment |
-
2013
- 2013-04-14 CN CN201380030774.2A patent/CN104519886B/zh not_active Expired - Fee Related
- 2013-04-14 IN IN8562DEN2014 patent/IN2014DN08562A/en unknown
- 2013-04-14 CA CA2870303A patent/CA2870303A1/en not_active Abandoned
- 2013-04-14 US US14/394,470 patent/US20150080404A1/en not_active Abandoned
- 2013-04-14 EP EP13776189.6A patent/EP2836211B1/en active Active
- 2013-04-14 WO PCT/US2013/036512 patent/WO2013155504A1/en not_active Ceased
- 2013-04-14 WO PCT/US2013/036514 patent/WO2013155505A1/en not_active Ceased
- 2013-04-14 EP EP20190036.2A patent/EP3791879A1/en active Pending
- 2013-04-14 EP EP13776208.4A patent/EP2836212A4/en not_active Ceased
- 2013-04-14 EP EP13776297.7A patent/EP2836213B1/en active Active
- 2013-04-14 WO PCT/US2013/036515 patent/WO2013155506A1/en not_active Ceased
- 2013-04-14 JP JP2015505972A patent/JP6242855B2/ja active Active
- 2013-04-14 MX MX2014012374A patent/MX2014012374A/es unknown
- 2013-04-14 JP JP2015505973A patent/JP2015514135A/ja not_active Withdrawn
- 2013-04-14 AU AU2013245702A patent/AU2013245702A1/en not_active Abandoned
- 2013-04-14 US US14/394,469 patent/US11053245B2/en active Active
- 2013-04-14 KR KR1020147031752A patent/KR20140146192A/ko not_active Withdrawn
- 2013-04-14 JP JP2015505971A patent/JP6334511B2/ja active Active
- 2013-04-14 RU RU2014145682A patent/RU2014145682A/ru not_active Application Discontinuation
- 2013-04-14 US US14/394,467 patent/US9428506B2/en active Active
- 2013-04-14 ES ES13776189T patent/ES2727815T3/es active Active
-
2018
- 2018-06-05 JP JP2018107717A patent/JP2018168161A/ja not_active Withdrawn
-
2019
- 2019-09-27 US US16/585,251 patent/US11124514B2/en active Active
-
2020
- 2020-07-10 US US16/926,552 patent/US20210002280A1/en active Pending
- 2020-07-10 US US16/926,551 patent/US20200407362A1/en active Pending
-
2021
- 2021-03-08 JP JP2021035948A patent/JP2021098724A/ja active Pending
- 2021-08-18 US US17/405,736 patent/US11958852B2/en active Active
-
2023
- 2023-08-24 JP JP2023136052A patent/JP2023159345A/ja active Pending
-
2024
- 2024-03-11 US US18/601,923 patent/US20240208974A1/en active Pending